Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD

Bone Marrow Transplantation

Volumn 44, Issue 12, 2009, Pages 813-819

  Jacobsohn, D A ^a   Rademaker, A ^a   Kaup, M ^b   Vogelsang, G B ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chronic GVHD; Graft versus host disease; NIH consensus criteria; Scale

Indexed keywords

CORTICOSTEROID; PENTOSTATIN;

ARTICLE; BODY SURFACE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; ERYTHEMA; FASCIITIS; HUMAN; NATIONAL HEALTH ORGANIZATION; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RASH; RATING SCALE; SCLERODERMA; SKIN MANIFESTATION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; CONSENSUS DEVELOPMENT CONFERENCES, NIH AS TOPIC; DRUG RESISTANCE; ERYTHEMA; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LICHEN SCLEROSUS ET ATROPHICUS; MALE; PENTOSTATIN; PROSPECTIVE STUDIES; SKIN; UNITED STATES;

EID: 75049084093     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.84     Document Type: Article

References (12)

1. Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004; 73: 56-61.
2. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006; 107: 3074-3080.
3. Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 47-55.
4. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D et al. Rituximab for steroid-refractory chronic graft-versushost disease. Blood 2006; 108: 756-762.
5. Jacobsohn DA, Chen AR, Zahurak M, Piantadosi S, Anders V, Bolanos-Meade J et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versushost disease. J Clin Oncol 2007; 25: 4255-4261.
6. Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008; 112: 2667-2674.
7. Jagasia M, Giglia J, Chinratanalab W, Dixon S, Chen H, Frangoul H et al. Incidence and outcome of chronic graftversus- host disease using National Institutes of Health Consensus criteria. Biol Blood Marrow Transplant 2007; 13: 1207-1215.
8. Arora M, Nagaraj S, Witte J, Defor TE, Macmillan M, Burns LJ et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant 2009; 43: 149-153.
9. Cho BS, Min CK, Eom KS, Kim YJ, Kim HJ, Lee S et al. Feasibility of NIH consensus criteria for chronic graft-versushost disease. Leukemia 2009; 23: 78-84.
10. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12: 252-266. (Pubitemid 43273710)
11. Greinix HT, Pohlreich D, Maalouf J, Soukup P, Supper V, Kalhs P et al. A single-center pilot validation study of a new chronic GVHD skin scoring system. Biol Blood Marrow Transplant 2007; 13: 715-723.
12. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-1285.